Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 9.83
0.821 %
$ 48.8 M
Market Cap
-109.22
P/E
1. INTRINSIC VALUE
Balance Sheet
Daxor Corporation
| Current Assets | 0 |
| Cash & Short-Term Investments | 0 |
| Receivables | 9.68 K |
| Other Current Assets | -9.68 K |
| Non-Current Assets | 0 |
| Long-Term Investments | 36.6 M |
| PP&E | 0 |
| Other Non-Current Assets | -36.6 M |
| Current Liabilities | 0 |
| Accounts Payable | 0 |
| Short-Term Debt | 0 |
| Other Current Liabilities | 0 |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Daxor Corporation
| Revenue | 2.13 M |
| Cost Of Revenue | 0 |
| Gross Profit | 2.13 M |
| Operating Expenses | 1.59 M |
| Operating Income | 536 K |
| Other Expenses | 0 |
| Net Income | 536 K |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Daxor Corporation
| Net Income | 536 K |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 14.1 K |
| Others | -515 K |
| Free Cash Flow | 25.7 K |
Wall Street Analysts Price Targets
Daxor Corporation
DXR has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.03 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Daxor Corporation
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
50.1 K USD 2
3-6 MONTHS
0 USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients.
globenewswire.com
- 1 month ago
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume measurement technology, announces the expansion of its innovative diagnostic solutions into two additional U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients nationwide. Daxor continues to drive healthcare transformation through its dual implementation models, tailored to meet the unique needs of diverse clinical settings.
globenewswire.com
- 1 month ago
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision and enhancing treatment outcomes for a spectrum of conditions.
globenewswire.com
- 2 months ago
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
Daxor's Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant expansion of its blood volume analysis (BVA) capabilities in three new hospitals. This growth is accelerated by the widespread adoption of Daxor's ezBVA Lab service – a cutting-edge, CLIA-certified facility delivering precise, on-demand blood volume analysis results within 24 hours.
globenewswire.com
- 2 months ago
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung disease treatment for four days of innovative research and knowledge exchange.
globenewswire.com
- 2 months ago
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation
globenewswire.com
- 2 months ago
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data presented at the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. Research from The Minneapolis Heart Institute Foundation® and Allina Health Minneapolis Heart Institute® demonstrated that hospitalized heart failure patients who received blood volume analysis (BVA) prior to hospital discharge could be used to stratify those with a substantially better survival rate.
globenewswire.com
- 2 months ago
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo
BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation
globenewswire.com
- 3 months ago
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
Regional Medical Leaders Embrace Daxor's ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into three regional healthcare facilities across the U.S. These facilities will use Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility equipped with state-of-the-art technology. The ezBVA Lab delivers comprehensive blood volume analysis (BVA) results within 24 hours for both inpatient and outpatient settings, improving patient outcomes while reducing costs.
globenewswire.com
- 3 months ago
Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript
Daxor Corporation (NASDAQ:DXR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Michael Feldschuh - Chief Executive Officer Bob Michel - Chief Financial Officer John Jefferies - Chief Medical Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2024.
seekingalpha.com
- 4 months ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023.
globenewswire.com
- 4 months ago
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments.
globenewswire.com
- 4 months ago
8. Profile
Summary
Daxor Corporation DXR
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 48.8 M
Dividend Yield
0.00%
Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Contact
109 Meco Lane, Oak Ridge, TN, 37830
https://www.daxor.com
IPO
Date
July 25, 1983
Employees
37
Officers
Mr. Michael Richard Feldschuh
Chairman, President & Chief Executive Officer
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer & Director
Mr. Robert J. Michel CPA, CPA, M.B.A.
Chief Financial Officer, Chief Compliance Officer & Corporate Secretary
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H.
Chief Medical Officer
Ms. Kathryn A. Kornafel
Senior Vice President of Marketing & Commercial Development
Ms. Linda Cooper
Vice President of Development & Operations